Capricor/$CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ticker
$CAPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
160
ISIN
US14070B3096
Website
Capricor Metrics
BasicAdvanced
$508M
-
-$1.42
0.86
-
Price and volume
Market cap
$508M
Beta
0.86
52-week high
$21.01
52-week low
$3.52
Average daily volume
2.6M
Financial strength
Current ratio
6.548
Quick ratio
6.484
Long term debt to equity
0.319
Total debt to equity
0.979
Management effectiveness
Return on assets (TTM)
-35.24%
Return on equity (TTM)
-75.39%
Valuation
Price to revenue (TTM)
24.841
Price to book
3.98
Price to tangible book (TTM)
3.98
Price to free cash flow (TTM)
-9.143
Growth
Revenue change (TTM)
-35.92%
Earnings per share change (TTM)
65.27%
3-year revenue growth (CAGR)
339.82%
3-year earnings per share growth (CAGR)
13.88%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Capricor News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out
Accesswire·3 hours ago
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
Seeking Alpha·12 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $508M as of May 22, 2025.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of May 22, 2025.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of May 22, 2025.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.